CHF 6333

Drug Profile

CHF 6333

Alternative Names: CHF-6333

Latest Information Update: 04 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chiesi Farmaceutici
  • Class Antibronchitics; Antifibrotics
  • Mechanism of Action Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Bronchiectasis; Cystic fibrosis

Most Recent Events

  • 18 May 2018 Pharmacodynamics data from preclinical studies in Cystic fibrosis presented at the 114th International Conference of the American Thoracic Society (ATS-2018)
  • 01 Jul 2017 Chiesi Farmaceutici completes the phase I CHF6333 FIH trial in Bronchiectasis and Cystic fibrosis (In volunteers) in Belgium (Inhalation) (NCT03056326)
  • 01 Nov 2016 Phase-I clinical trials in Cystic fibrosis (In volunteers) in Belgium (Inhalation) (NCT03056326)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top